Articles
High-Dose Versus Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults
Influenza causes substantial morbidity and mortality,1 particularly in high-risk groups such as older adults and individuals with cardiovascular disease (CVD).
The high-dose inactivated influenza vaccine (HD-IIV) has demonstrated superior protection against a range of hospitalisation endpoints versus standard-dose inactivated influenza vaccine (SD-IIV), but its effectiveness against specific cardiovascular outcomes and in those with pre-existing cardiovascular disease (CVD) is not well elucidated.
Click here to access the article.